Details for New Drug Application (NDA): 022206
✉ Email this page to a colleague
The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the silodosin profile page.
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 4MG | ||||
| Approval Date: | Oct 8, 2008 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 8MG | ||||
| Approval Date: | Oct 8, 2008 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 022206
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | ⤷ Start Trial | ⤷ Start Trial |
| Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | ⤷ Start Trial | ⤷ Start Trial |
| Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | ⤷ Start Trial | ⤷ Start Trial |
| Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | ⤷ Start Trial | ⤷ Start Trial |
| Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-002 | Oct 8, 2008 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
